The predictive value of angiogenesis for adjuvant therapy in breast cancer

Breast Cancer

Volumn 7, Issue 4, 2000, Pages 311-314

  Toi, Masakazu ^a   Bando, Hiroko ^a   Kuroi, Katsumasa ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Agiogenesis; Thymidine phosphorylase; Vasular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN; VASCULOTROPIN A;

BREAST TUMOR; FEMALE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROGNOSIS; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; BREAST NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; THYMIDINE PHOSPHORYLASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034565470     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02966396     Document Type: Review

References (18)

1. Zhang L, Kharbanda S, McLeskey SW, et al: Overexpression of fibroblast growih factor I in MCF-7 breast cancer cells facilitates tumor cell dissemination but does not support the development of macrometastases in the lungs or lymph nodes. Cancer Res 59: 5023-5029, 1999. (Pubitemid 29472910)
2. McLeskey SW, Zhang L, Kharbanda S, et al: Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat 39: 103-117, 1996. (Pubitemid 26136508)
3. Zhang HT, Craft P, Scott PA, et al: Enhancement of tumor growih and vascular density by transfection of vascular endothelial cell growih factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 87:213-219, 1995.
4. Gasparini, G, and Harris, AL: Clinical Importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol13:765-782, 1995.
5. Haraguchi M, Furukawa T, Sumizawa T, et al: Sensitivity of human KB cells expressing platelet-derived endothelial cell growih factor to pyrimidine antimetabolites. Cancer Res, 53:5680-5682, 1993. (Pubitemid 23360271)
6. Sawada N, Ishikawa T, Fukase Y, et al: Increased sensitivity to the prodrug 5’-deoxy-5-fluorouridine and modulation of 5-fluor0-2r-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 72:669-675, 1995.
7. Yonekura K, Basaki Y, Chikahisa L, et al: UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinomE-as determined by a dorsal air sac assay in mice. Clin Cancer Res 5:2185-2191, 1999. (Pubitemid 29399276)
8. Gasparini G, Toi M, Gion M, et al: Prognostic significance of vascular-endothelial growih factor protein in node-negative breast carcinoma J Natl Cancer Inst 89:139-147, 1997. (Pubitemid 27034790)
9. Toi M, Gion M, Biganzoli E, et al: Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growih factor in node-negative breast cancer: Prognostic implications. Angiogenesis 1:71-83, 1997. (Pubitemid 127505703)
10. Gasparini G, Toi M, Miceli R, et al: Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J SciAm 5:101-101, 1999.
11. Linderholm B, Lindh B, Tavelin B, et al: P53 and vascular-endothelial- growih-factor (VEGF) 6xpression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 89:51-62, 2000. (Pubitemid 30078750)
12. Clahsen PC, van de Velde CJ, Dural C, et al: P53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with nodenegative early breast cancer. J Clin Oncol 16:470-479, 1998. (Pubitemid 28135588)
13. Makris A, Powles TJ, Kakolyis S, et al: Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer 85:1996-2000, 1999. (Pubitemid 29202775)
14. Fox SB, Engels K, Comley M, et al: Relationship of elevated tumour thynidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol 8:271-275, 1997. (Pubitemid 27153494)
15. Yamamoto Y, Toi M, Tominaga T: Prediction ofthe effect of 5’-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients. Oncology Reports 3:863-865, 1996. (Pubitemid 26323740)
16. Eppenbergef, U, Kueng, et al: Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets ofnode-negative breast cancer patients. J Clin Oncol 16:3129-3136, 1998.
17. Gasparini G, Fox SB, Verderio P, et al: Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 2: 1191-1198, 1996. (Pubitemid 26238451)
18. Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res, 2:1843-1849, 1996. (Pubitemid 26384151)